Flagship Pioneering has created a dual role as CEO-partner of the firm and CEO of Cellarity, one of its spinouts, and named Fabrice Chouraqui to the position.
Chouraqui was most recently president of the US pharmaceuticals business for Novartis (NYSE: [[ticker:NVS]]), a role from which he stepped down last August. Previously he held other leadership positions at Novartis and, prior to that, at Bristol-Myers Squib (NYSE: [[ticker:NVS]]).
At Cellarity, which Flagship founded in 2017 and debuted in late 2019, Chouraqui will work alongside founding CEO Avak Kahvejian, a general partner at Flagship, on its efforts to use digital modeling of cell behaviors to design new therapies.
Earlier this year Flagship, a venture capital firm known for starting and spinning out biotechs, raised $1.1 billion for its seventh fund.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
